Navigation Links
Immunetics Wins $2.8 Million Contract for New Type of HIV Test
Date:5/18/2010

Boston-based Immunetics won a $2.8 million contract from the National Institutes of Health to develop a new test for HIV that will prevent a false positive diagnosis in individuals who have received HIV vaccines in clinical trials. The vaccine response alone results in a false positive result with current HIV tests, resulting in erroneous diagnosis.

Boston, Mass (PRWEB) May 18, 2010 -- Immunetics, Inc. (Boston, MA) has been selected to receive a $2.8 million contract as part of the National Heart, Lung, and Blood Institute’s (NHLBI) Retrovirus Epidemiology Donor Study-II (REDS-II) project, a long term epidemiologic study of blood safety involving HIV and other infectious and non-infectious complications of blood transfusion.

The contract will be administered by Westat, a research organization based in Rockville, MD, which is the coordinating center for the REDS-II project. Under the contract, Immunetics will develop and supply a new test for HIV, which will uniquely distinguish individuals infected with HIV from those who have been immunized with experimental HIV vaccines in clinical trials. At present, vaccination leads to a false positive result on the current generation of HIV screening tests, a problem highlighted by recent publications in medical journals.

Clinical trials for HIV vaccines have involved thousands of vaccine recipients worldwide and continue to enroll more subjects, who stand to benefit from availability of the new test. The NHLBI initiated this project because it will provide a test which will be useful in screening blood donors in those regions of the world where HIV vaccine trials have been or are being conducted and to avoid the permanent deferral of those donors found not to be infected with HIV. Immunetics will work with a consortium of researchers at the National Institutes of Health, the Food and Drug Administration’s Center for Biologics Evaluation and Research where the original research leading to the new test was carried out, Blood Systems Research Institute in San Francisco, and others. The contract is valued at $9.2 million with all options exercised.

“This contract award presents a major opportunity for Immunetics and will leverage our longtime experience in the field of HIV diagnostics and assay development” said Dr. Andrew Levin, Immunetics' CEO and Scientific Director who will be the Principal Investigator on the project. “We see a great fit between our technology and the basic scientific advances made by the research teams at CBER and NIH. Given the vital need for an effective HIV vaccine, the test which we will be developing could play an essential role in current and future vaccine trials. We are particularly pleased to announce this award today, which has been designated by the NIH as National HIV Vaccine Awareness Day, and are very excited by the potential to make a significant contribution to public health in this area.”

Immunetics offers state-of-the-art assay technology for infectious disease diagnosis and pathogen detection, and for over ten years has been a leading innovator of tests for bacterial, viral and parasitic diseases. The company produces and markets a range of infectious disease assay kits and instruments. Its mission is better, cost-efficient care through more accurate diagnosis.

Contact: Andrew Levin - 617-896-9100 ext. 13 or alevin(at)immunetics(dot)com

# # #

Read the full story at http://www.prweb.com/releases/2010/05/prweb4015214.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related medicine news :

1. Safe & Secure Online Pharmacy Viamedic.com; Reaches Milestone of 1.5 Million Orders Processed
2. More Than 1 Million Invitations Anticipated for National ‘Back To Church Sunday,' Set for Sept. 12
3. Millions Are Losing Their Hearing Unnecessarily; Noise-Induced Hearing Loss Is Always Preventable, Says HearUSA Audiologist
4. Infectious diseases caused two-thirds of the nearly 9 million child deaths globally in 2008
5. Enter One Year Auction Contest; You Could Win 5% of Winning Bid or Buy Now - $1 Million Option Proceeds
6. $18.5 Million New Jersey Medical Malpractice Birth Injury Verdict Due To Cerebral Palsy Caused By A Delayed C-Section
7. $1.9 million grant to help UCF find multiple sclerosis nerve-ana
8. NIH awards $2.7-million grant to Kent State to study cognitive impairment in heart failure patients
9. MU awarded $8.5 million to explore tiny vessels role in cardiovascular diseases
10. Hutchinson Center receives $10.24 million from NIH for Latina breast cancer research
11. NIH awards $10 million to Rush University Medical Center to address health disparities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... Falls Church, VA (PRWEB) , ... ... ... to Integrate FDA Device Approval and Reimbursement , **An FDAnews Webinar**, Feb. ... , What are the critical reimbursement questions manufacturers should be asking ...
(Date:2/17/2017)... Seattle, WA (PRWEB) , ... February 17, 2017 ... ... health management organizations, has been named a finalist in the 8th Annual DecisionHealth ... impacting America's healthcare delivery system. Qualis Health’s work is recognized across multiple award ...
(Date:2/17/2017)... Tx (PRWEB) , ... February 17, 2017 , ... ... revenue cycle management services, announced today that Karen Pilley has been promoted to ... is critical in today’s shifting healthcare paradigm – a shift that demands the ...
(Date:2/17/2017)... ... February 17, 2017 , ... Cancer ... Molecular Medicine Tri-Conference February 20 – 22 in San Francisco. As part of ... anatomic and molecular pathology workflow solution, as well as its new precision medicine ...
(Date:2/17/2017)... ... February 17, 2017 , ... The Mason Pasquin Agency, ... and business owners in and around the Hampton Roads metropolitan region, is joining ... forms of domestic violence. , There are multiple categories of domestic violence – ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... 17, 2017 Research and Markets has announced the ... report to their offering. ... The report provides separate comprehensive analytics for the US, Canada ... Asia-Pacific , and Rest of World. Annual estimates and ... historic analysis is provided for these markets. Market data and analytics are ...
(Date:2/17/2017)... ST. LOUIS , Feb. 17, 2017   ... hospitals, has announced a new partnership with Engage ... the United States . FormFast will serve ... part of Engage,s implementations with MEDITECH .  ... that provides essential functionality to complement and enhance the ...
(Date:2/17/2017)... NEW YORK , Feb. 17, 2017  Noble ... coverage on ESSA Pharma Inc. (Nasdaq: EPIX ... Biotechnology Research, Kumar Raja , PhD. ... treatments for castration resistant prostate cancer (CRPC). Its lead ... selectively blocks the amino-terminal domain of the androgen receptor, ...
Breaking Medicine Technology: